UCB Pharma scored an exit after the bone disease therapy developer floated at the top of its range, having secured $92.5m in funding over the past two years.
Canada-based bone disease treatment developer Clementia Pharmaceuticals raised $120m yesterday in an initial public offering in the US that provided an exit for biopharmaceutical company UCB Pharma.
The company priced 8 million shares at $15.00 each, at the top of the IPO’s $13 to $15 range, and the underwriters have a 30-day option to buy another 1.2 million share which would boost the size of the offering to $138m.
Clementia plans to put $65m of the proceeds toward phase 3…
